Background theses for the formulation of guidelines on diagnosis and therapy metabolic bone disease as a part of CKD-MBD, with specific focus on low mineral bone content in DXA examination

Authors: Palička Vladimír 1;  Sulková Dusilová Sylvie 2,3;  Brunerová Ludmila 4
Authors‘ workplace: Osteocentrum, Ústav klinické biochemie a diagnostiky LF UK a FN Hradec Králové 1;  Hemodialyzační středisko FN Hradec Králové 2;  Katedra interních oborů LF UK, Hradec Králové 3;  II. interní klinika FNKV a 3. LF UK, Praha 4
Published in: Clinical Osteology 2019; 24(4): 169-177


The paper brings the basal background for the interdisciplinary cooperation between clinical osteology and nephro­logy in the field of metabolic osteopathy in kidney patients. Traditionally, renal bone disease is presented as a result of missing excretory, as well as endocrine renal function. Its main cause is secondary hyperparathyroidism, resp. disordered function of parathyroid glands. The term CKD-MBD, promoted in 2006, take into account the association between bone disorder and its systemic consequences, namely cardiovascular. The indication for the DXA assessment in kidney patients is growing. Low bone mineral content, however, is not representative for the severity of hyperparathyreosis, but it brings important information about associated or even dominating osteoporosis. It has been proven that renal patients may suffer from any other metabolic disease, not being associated with renal function. Clinical osteology focused on metabolic bone diseases. The most common bone disease is osteoporosis. As stated above, this osteoporosis may be modifying or even dominating finding also in patients with chronic kidney disease and even renal failure. The association with growing age of dialysis patients, with more common hormonal and nutritional disorders, long-lasting vitamin D deficiency, but also with the increasing frequencies of corticosteroid treatments, can be associated with the low bone mineral content in these patients. Low bone mineral content in DXA assessment is diagnostics for osteoporosis. Therapy of osteoporosis in physiological renal function follows its rules. However, osteoporosis itself, i.e. low bone mineral density, we found also in patients with chronic kidney disease and even in patients with kidney failure. In these patients, there is no necessary the link to traditional causes of renal osteodystrophy. Therapy of renal bone disease associated with functional derangement of parathyroid glands in kidney patients is well known. The same is true for the diagnosis and treatment of osteoporosis in basic population. However, practical recommendations for the treatment osteoporotic component, resp. renal osteopathy with low bone mineral content, are still lacking. The aim of this paper is to formulate the background for the wide discussion of experts. This should lead to formulation of concrete and practical recommendations for the treatment of osteoporosis (defined as osteopathy with DXA proven low bone mineral density) in patients with chronic renal disease as well as renal failure.


osteoporosis – bisphosphonates – dialysis – antiosteoresorptive therapy – chronic renal disease (CKD) – denosumab – densitometry (DXA) – low bone mineral content – renal osteodystrophy – secondary hyperparathyroidism

  1. Cunningham J, Locatelli F, Rodriquez M. Secondary hyperparathyoidism: pathogenesis, disease progression and therapeutic options. Clin J Am Soc Nephrol 2011; 6(4): 913–921. Dostupné z DOI: <>.
  2. Hruska KA, Teitelbaum SL. Renal Osteodystrophy. N Engl J Med 1995; 333(3): 166–174. Dostupné z DOI: <>.
  3. Moe SM, Drueke TB et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69(11): 1945–1953. Dostupné z DOI: <>.
  4. Cunningham J, Sprague SM, Cannata-Andia J et al. [Osteoporosis Work Group]. Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004; 43(3): 556–571. Dostupné z DOI: <>. Komentář in: Dusilová-Sulková S. Osteoporóza a selhání ledvin. Postgrad Nefrol 2004; 2(4): 50–51.
  5. Štěpánková J, Brunová J. Léčba osteoporózy u dialyzovaných pacientů. Postgrad Nefrol 2019; 17(4): 7–9.
  6. Moe SM. Renal Osteodystrophy or Kidney-Induced Osteoporosis? Curr Osteoporos Rep 2017; 15(3): 194–197. Dostupné z DOI: <–017–0364–1>.
  7. Miller PD. Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis 2014; 64(2): 290–304. Dostupné z DOI: <>.
  8. Brunerová L, Palička V, Dusilova-Sulkova S. Commentary on management of osteoporosis in advanced CKD: common view of a nephrologist and bone specialist. Endocrine Practice 2019, 25 (2): 193–196. Dostupné z DOI: <–0311>.
  9. [Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group]. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; (113): S1-S130. Dostupné z DOI: <>.
  10. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int 2017; 7(1): 1–59. Dostupné z DOI: <>. Erratum in Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2017; 7: 1–59. Dostupné z WWW: <>.
  11. Festuccia F, Jafari MT, Moioli A et al. Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol 2017; 30(2): 271–279. Dostupné z DOI: <–016–0334–1>.
  12. Ritter CS, Slatopolsky E. Phosphate toxicity in CKD: the killer among us. Clin J Am Soc Nephrol 2016; 11(6): 1088–1100. Dostupné z DOI: <>.
  13. Nitta K, Yajima A, Tsuchiya K. Management of Osteoporosis in Chronic Kidney Disease. Intern Med 2017; 56(24): 3271–3276. Dostupné z DOI: <–16>.
  14. Bergner R. Bisphosphonate therapy in renal osteodystrophy – a review. J Nephrol 2013; 26(3): 450–455. Dostupné z DOI: <>.
  15. Brunerová L, Ronová P, Verešová J et al. Osteoporosis and Impaired Trabecular Bone Score in Hemodialysis Patients. Kidney Blood Press Res 2016; 41(3): 345–354. Dostupné z DOI: <>.
  16. Aleksova J, Kurniawan S, Elder GJ. The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease. Osteoporos Int 2018; 29(6): 1447–1455. Dostupné z DOI: <–018–4468-y>.
  17. Bouquegneau A, Salam S, Delanaye P et al. Bone disease after kidney transplantation. Clin J Am Soc Nephrol 2016; 11(7): 1282–1296. Dostupné z DOI: <>.
  18. Nakai K, Fujii H, Ishimura T et al. Incidence and Risk Factors of Persistent Hyperparathyroidism After Kidney Transplantation. Transplant Proc 2017; 49(1): 53–56. Dostupné z DOI: <>.
  19. Brunova J, Kratochvilova S, Stepankova J. Osteoporosis Therapy with Denosumab in Organ Transplant Recipients. Front Endocrinol (Lausanne) 2018; 9:162. Dostupné z DOI: <>.
  20. Kan SL, Ning GZ, Chen LX et al. Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis. Medicine (Baltimore) 2016; 95(5): e2679. Dostupné z DOI: <>.
  21. Pimentel A, Ureña-Torres P, Zillikens MC et al. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney Int 2017; 92(6): 1343–1355. Dostupné z DOI: <>.
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account